Q-omics provides the consensus-scored TSPAN17 profile across patient tissues and cancer cell-line models. TSPAN17 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TSPAN17 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, TSPAN17 RNA expression shows 18,657 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, HNSC, and ACC as cancer lineages where TSPAN17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN17 survival associations across molecular data types. TSPAN17 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN17 RNA expression–survival associations across cancer types. High TSPAN17 expression shows unfavorable associations in UVM, KICH, HNSC, LGG and MESO, but favorable associations in STAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TSPAN17 RNA expression.
This table summarizes TSPAN17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN17 shows higher tumor expression in HNSC, LIHC, KIRP, BLCA, LUAD and STAD. The HNSC box plot shows higher TSPAN17 RNA expression in tumor versus normal tissue (log2 FC = +0.823, t-test p < 0.001).
This table shows molecular features associated with TSPAN17 in patient tissues and cancer cell lines. In patient samples, TSPAN17 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
